Vaxart: innovative patentierte Impfung (Covid-19 etc.) per Tablette (Seite 52)
eröffnet am 04.03.17 01:19:22 von
neuester Beitrag 31.01.24 18:00:17 von
neuester Beitrag 31.01.24 18:00:17 von
Beiträge: 525
ID: 1.248.054
ID: 1.248.054
Aufrufe heute: 0
Gesamt: 59.931
Gesamt: 59.931
Aktive User: 0
ISIN: US92243A2006 · WKN: A2JD8X · Symbol: VXRT
0,8220
USD
-0,87 %
-0,0072 USD
Letzter Kurs 02:00:00 NMS
Neuigkeiten
| Titel |
|---|
23.05.24 · globenewswire  |
13.05.24 · globenewswire |
07.05.24 · globenewswire |
30.04.24 · globenewswire |
28.03.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0450 | +14.021,62 | |
| 4,9600 | +41,71 | |
| 1,3000 | +26,21 | |
| 1,6700 | +25,56 | |
| 2,9350 | +22,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,9300 | -17,16 | |
| 2,1200 | -18,46 | |
| 9,6000 | -18,64 | |
| 1,4600 | -24,56 | |
| 1,7000 | -31,17 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 60.142.068 von faultcode am 19.03.19 17:28:09Warst du bei BPTH auch dabei? War auch ei satter Anstieg.....
Antwort auf Beitrag Nr.: 60.140.349 von Miser am 19.03.19 15:01:51
https://investors.vaxart.com/news-releases/news-release-deta…
--> ist nur eine Ankündigung, könnte aber einen Short squeeze ausgelöst haben:
=>
...“The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step..."
--> zuletzt so ~10% vom Float
wegen: Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
19.3.https://investors.vaxart.com/news-releases/news-release-deta…
--> ist nur eine Ankündigung, könnte aber einen Short squeeze ausgelöst haben:
=>
...“The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step..."
--> zuletzt so ~10% vom Float
Satter Anstieg heute.... 
Antwort auf Beitrag Nr.: 58.883.277 von faultcode am 05.10.18 22:42:44
Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
https://www.wallstreet-online.de/nachricht/11224623-vaxart-a…
=> VXRT nun mit "Going concern" --> der Begriff taucht über zehnmal im 10-K auf:
https://investors.vaxart.com/annual-reports-and-proxies
z.B.:
We believe that there is substantial doubt about our ability to continue as a going concern. (PDF 49/151)
--> das war 2016 und 2017 (bei damals noch Aviragen Therapeutics) noch nicht der Fall
=> der verbliebende Cash ist hier bald weg
Going concern
Zu:Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
https://www.wallstreet-online.de/nachricht/11224623-vaxart-a…
=> VXRT nun mit "Going concern" --> der Begriff taucht über zehnmal im 10-K auf:
https://investors.vaxart.com/annual-reports-and-proxies
z.B.:
We believe that there is substantial doubt about our ability to continue as a going concern. (PDF 49/151)
--> das war 2016 und 2017 (bei damals noch Aviragen Therapeutics) noch nicht der Fall
=> der verbliebende Cash ist hier bald weg
von gestern:
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
https://www.wallstreet-online.de/nachricht/10906002-new-data…
=>
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018....
Trading Spotlight
Antwort auf Beitrag Nr.: 57.598.041 von faultcode am 21.04.18 16:49:30
4.6.
Vaxart shares sink after underwhelming results from clinical trials of its antiviral drug
http://www.proactiveinvestors.com/companies/news/198216/vaxa…
ATL
z.B. auch wg.:4.6.
Vaxart shares sink after underwhelming results from clinical trials of its antiviral drug
http://www.proactiveinvestors.com/companies/news/198216/vaxa…
Antwort auf Beitrag Nr.: 57.051.827 von faultcode am 17.02.18 16:55:38
http://investors.vaxart.com/news-releases/news-release-detai…
--> Tagesgewinn: läppische +3.5%
...Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir, a single dose product licensed in Japan to prevent or treat influenza infection, exceeded ¥20 billion in the fiscal year 2017, triggering a $5 million milestone payment to Vaxart.
The payment is expected in the second quarter of 2018 and is in accordance with the terms of the 2009 Commercialization Agreement between Daiichi Sankyo and Biota Pharmaceuticals, a company recently acquired by Vaxart.
“Daiichi Sankyo, our partner for Inavir in Japan, has successfully built a strong franchise in the influenza sector since the launch of Inavir in 2010, and is now the market leader in Japan,” said Wouter Latour, chief executive office of Vaxart.
“We expect Inavir to continue to generate meaningful royalty revenue for Vaxart over the coming years, and we congratulate our colleagues at Daiichi Sankyo with these excellent results.”...
--> https://www.daiichisankyo.com/
--> Aktie lief zuletzt gut, aber operativ läuft es dort nicht --> Auslaufen von guten Alt-Patenten --> keine neuen Blockbuster (auch ein wohl schwieriger Partner mit schwieriger Vergangenheit --> siehe Ranbaxy-Katastrrophe...)
Vaxart Announces Million Inavir Revenue Milestone
April 20, 2018 08:00 AM Eastern Daylight Timehttp://investors.vaxart.com/news-releases/news-release-detai…
--> Tagesgewinn: läppische +3.5%
...Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir, a single dose product licensed in Japan to prevent or treat influenza infection, exceeded ¥20 billion in the fiscal year 2017, triggering a $5 million milestone payment to Vaxart.
The payment is expected in the second quarter of 2018 and is in accordance with the terms of the 2009 Commercialization Agreement between Daiichi Sankyo and Biota Pharmaceuticals, a company recently acquired by Vaxart.
“Daiichi Sankyo, our partner for Inavir in Japan, has successfully built a strong franchise in the influenza sector since the launch of Inavir in 2010, and is now the market leader in Japan,” said Wouter Latour, chief executive office of Vaxart.
“We expect Inavir to continue to generate meaningful royalty revenue for Vaxart over the coming years, and we congratulate our colleagues at Daiichi Sankyo with these excellent results.”...
--> https://www.daiichisankyo.com/
--> Aktie lief zuletzt gut, aber operativ läuft es dort nicht --> Auslaufen von guten Alt-Patenten --> keine neuen Blockbuster (auch ein wohl schwieriger Partner mit schwieriger Vergangenheit --> siehe Ranbaxy-Katastrrophe...)
Antwort auf Beitrag Nr.: 57.051.749 von faultcode am 17.02.18 16:42:07
* Vaxart had 30 mil in debt going into merger, those creditors took stock as payment @ the price of $15 per share
* Feb.16.2018:
Here's why it's so hard to make a better flu vaccine
https://www.nbcnews.com/health/health-news/here-s-why-it-s-s…
=>
...Another approach uses a pill instead of a needle.
The VXA-A1.1 vaccine being made by VaxArt doesn’t use eggs but employs an extra ingredient called an adjuvant to stimulate the immune system.
The company just finished a phase 2 study in people who agreed to try the pill vaccine and then be deliberately exposed to flu. It reduced the infection rate by 48 percent — not a home run, but better than the 38 percent reduction in people who got a standard seasonal flu vaccine...
Vaxart: andere Info's -- influenza pill
aus ST:* Vaxart had 30 mil in debt going into merger, those creditors took stock as payment @ the price of $15 per share
* Feb.16.2018:
Here's why it's so hard to make a better flu vaccine
https://www.nbcnews.com/health/health-news/here-s-why-it-s-s…
=>
...Another approach uses a pill instead of a needle.
The VXA-A1.1 vaccine being made by VaxArt doesn’t use eggs but employs an extra ingredient called an adjuvant to stimulate the immune system.
The company just finished a phase 2 study in people who agreed to try the pill vaccine and then be deliberately exposed to flu. It reduced the infection rate by 48 percent — not a home run, but better than the 38 percent reduction in people who got a standard seasonal flu vaccine...
Antwort auf Beitrag Nr.: 57.051.710 von faultcode am 17.02.18 16:32:22
MW:
* Market Cap: $23.04M
* Shares Outstanding: 38.65M
* Public Float: 3.48M
* Rev. per Employee: $487.5K
* EPS: $-5.39
GF:
* Price-to-Net-Cash 3.03
* Price-to-Net-Current-Asset-Value 2.17
* Price-to-Tangible-Book 2.13
* Price-to-Median-PS-Value 0.59
http://vaxart.com/
Vaxart: vorl. finanzielle Eckdaten
16.2.:MW:
* Market Cap: $23.04M
* Shares Outstanding: 38.65M
* Public Float: 3.48M
* Rev. per Employee: $487.5K
* EPS: $-5.39
GF:
* Price-to-Net-Cash 3.03
* Price-to-Net-Current-Asset-Value 2.17
* Price-to-Tangible-Book 2.13
* Price-to-Median-PS-Value 0.59
http://vaxart.com/
Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.
15.2.https://www.businesswire.com/news/home/20180213006751/en/Vax…
11 x US0537611024 (AVIR) --> 1 x US92243A2006 (VXRT)
=>
...Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen Therapeutics, Inc. In connection with the merger, Aviragen Therapeutics, Inc. changed its name to Vaxart, Inc. and effected a 1-for-11 reverse split of its common stock.
The combined company will commence trading on a post-reverse split basis effective at the opening of the market on February 14, 2018 on Nasdaq under the symbol “VXRT.”
“We are very pleased to complete this merger, which marks a significant milestone for Vaxart,” said Wouter Latour, M.D., president and chief executive officer of Vaxart. “The merger provides us with the necessary funding to support operations and enables us to advance the development of our pipeline of proprietary oral vaccines and direct-acting antivirals.
We expect to have several value-creating events this year, including a data readout from the Phase 2 study of BTA074, which we acquired in the merger, and the start of a Phase 2 norovirus challenge study.”...
=> erst mal alle vorherigen Gewinne wieder einkassiert:
Durchsuchen
Vaxart: innovative patentierte Impfung (Covid-19 etc.) per Tablette
